New COVID-19 Vaccine Shows Promise
An experimental COVID-19 vaccine protected monkeys from catching the viral infection, according to an unreviewed report. The new vaccine has now entered clinical trials in China to test the drug in humans.
Although the animal study, posted April 19 to the preprint database bioRxiv, has not been subject to formal review, scientists took to Twitter to share their first impressions.
“So, this is the first ‘serious’ preclinical data I have seen for an actual vaccine candidate,” Florian Krammer, a professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, tweeted on April 22. Before being tested in healthy humans, vaccines undergo so-called preclinical tests in animals. The experimental vaccine, developed by the Beijing-based company Sinovac Biotech, showed promising results in rhesus macaques before entering human trials, Krammer noted. “I’m a fan,” he added in another tweet.
Now in clinical trials, various doses of the vaccine will be given to 144 individuals to determine whether it’s safe, meaning it does not cause dangerous side effects, according to ClinicalTrials.gov. The vaccine would then move into efficacy trials with more than 1,000 additional people to determine whether it triggers an adequate immune response, commented Meng Weining, Sinovac’s senior director for overseas regulatory affairs.
The Sinovac vaccine contains an inactivated version of SARS-CoV-2, the virus that causes COVID-19. By introducing an inactive virus into the body, the vaccine should prompt the immune system to build antibodies that target the pathogen without triggering an actual COVID-19 infection. When given to mice, rats and rhesus macaques, the vaccine sparked the production of such antibodies, according to the bioRxiv report. “This is old-fashioned technology,” which would make the product easy to manufacture, Krammer wrote on Twitter. “What I like most is that many vaccine producers, also in lower–middle-income countries, could make such a vaccine,” he added in an interview